Skip to Main Content
An official website of the United States government
Login Change: CDAS is now using the NIH Researcher Auth Service (RAS) to manage our existing login options. When logging into CDAS, you will be taken to RAS, where you can select your preferred login provider to access CDAS.

Association of Human Endogenous Retrovirus K (HERV-K) Expression with Prostate Cancer Development and Progression

Principal Investigator

Name
Stefan Ambs

Degrees
-

Institution
-

Position Title
-

Email
ambss@mail.nih.gov

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
2009-0552

Initial CDAS Request Approval
Dec 15, 2009

Title
Association of Human Endogenous Retrovirus K (HERV-K) Expression with Prostate Cancer Development and Progression

Summary
Research in our laboratory discovered a distinct gene signature in prostate tumors of African-American patients consistent with either a viral infection or reactivation of endogenous retroviruses in the tumor microenvironment 1. Human endogenous retroviral sequences (HERVs) comprise ~8% of our genome 2. Their reactivation has been observed in several human cancers 3-5. Of all known HERVs, HERV-K is the most intact and transcriptionally active endogenous retrovirus and can trigger an immune response 2,3,6. Expression differences for HERV-K amongst ethnic groups have been described, with some polymorphic HERV-K sequences being most frequently expressed in African populations 7. Given the association of HERV-K with human cancer and expression differences by ancestry, we investigated the association of HERV-K expression with prostate cancer in European-American and African-American men. In a pilot case-control study, HERV-K expression was evaluated from buffy coat in 294 prostate cancer cases and 135 population-based controls. This study found HERV-K to be significantly associated with prostate cancer in a dose-dependent manner among both African-American and European-American men. Furthermore, African-American controls had significantly higher HERV-K expression than European-American controls. The data suggest that HERV-K expression could be an unrecognized and significant pre-disposing factor in prostate cancer, or a disease effect. Because pre-diagnostic samples were not available in the pilot, we could not determine whether HERV-K expression precedes disease development. In any case, the findings from the pilot are novel and significant, and should be pursued in a larger setting. In this proposal, we aim to validate the association of HERV-K with prostate cancer. Moreover, we propose to investigate pre-diagnostic samples to determine if reactivation of HERV-K is a risk factor and marker of prostate cancer that precedes diagnosis. Finally, we propose to analyze HERV-K expression in early and advanced prostate cancer to examine whether the HERV-K burden increases with disease progression.

Aims

Primary Hypothesis: HERV-K expression in buffy coat is associated with prostate cancer development and progression in African-American (AA) and European-American (EA) men. Specific Aim 1: Examine the association between HERV-K expression and prostate cancer development in a) all men, b) EA men and c) AA men in PLCO using a nested case control design. Specific Aim 2: Examine whether HERV-K expression is a pre-diagnostic marker for prostate cancer. Specific Aim 3: Examine HERV-K expression in non-advanced versus advanced stage disease

Collaborators

Amanda Black (NCI, DCEG)
Paul Pinsky (NCI, DCEG)
Tiffany Wallace (NCI, CCR)
Stefan Ambs (NCI, CCR) - Current Lead Investigator (3/4/2013)

Related Publications